Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

Journal of Infectious Diseases

Volumn 184, Issue 11, 2001, Pages 1461-1464

  Razonable, Raymund R ^a   Rivero, Antonio ^a   Rodriguez, Aurelio ^a   Wilson, Jennie ^d   Daniels, Judith ^d   Jenkins, Gregory ^c   Larson, Timothy ^b   Hellinger, Walter C ^a   Spivey, James R ^e   Paya, Carlos V ^a,d  

^a Division of Infectious Diseases and Internal Medicine   (United States)

^b Division of Nephrology and Hypertension   (United States)

^c Section of Biostatistics   (United States)

^d MAYO CLINIC   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE ASSOCIATION; FEMALE; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; PRIORITY JOURNAL; RECIPIENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; FEMALE; FORECASTING; GANCICLOVIR; GRAFT REJECTION; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; KINETICS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 0035576910     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/324516     Document Type: Article

References (14)

1. Prevention of cytomegalovirus disease in recipients of solid-organ transplants
2. Infections in solid-organ transplant recipients
3. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation
4. The economic impact of cytomegalovirus infection after liver transplantation
5. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation
6. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
7. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
8. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
9. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
10. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
11. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients
12. Diagnosis and treatment of cytomegalovirus infection
13. Mycophenolate mofetil: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation
14. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo